Eleven of every twelve people who start GLP-1 weight-loss drugs will pause or stop taking them at some point, Noom reported — a stat the company is now building its newest ad around.

Why the tonal shift?

The spot trades Rebel Wilson's pastel-wardrobe goofiness, the centerpiece of earlier "Lose for Keeps" installments, for a dystopian mood. An influencer type revels in her weight-loss wins, then hears sinister whispers from her TV, smart speaker, smoke alarm and Roomba. Each device delivers the same warning: "Weight regain doesn't care."

The 30-second ad debuts today at ADWEEK House HQ. Noom's internal marketing team wrote the script and concept, then tapped director Nina Meredith and Shutterstock Studios to execute the creative vision. Chief Brand Officer Rachel Mahoney told ADWEEK that a more ghostly iteration tested flat, but the smart-home paranoia concept landed.

"The message was even clearer when the tone was heightened a little bit more," Mahoney said. "People recognized that this is something that could be a fearful part of a weight loss journey, but then [the spot] sets up Noom really well to be a solution at the end."

What's the GLP-1 hook?

Noom has always sold habit change, but it entered the drug market in 2023 with Noom Med. The new ad keeps that habit-first message while nodding to the discontinuation problem. Mahoney framed the spot as a public-service announcement aimed at patients before they fill a prescription.

"Most people aren't thinking about stopping a GLP-1 when they're starting a GLP-1," she said. "This PSA is really about the questions you should be asking, or things you should be thinking about, before you make your choice."

Does the habit-plus-drug claim hold up?

Noom's internal research suggests it does. Members who kept practicing Noom habits after stopping a GLP-1 retained more weight than non-Noomers who quit the medication, the company reported. The new campaign will pair the ad with patient testimonials from YouTube, all featuring members who lost weight by combining habit change and GLP-1s.

Side effects, insurance limits and life changes routinely override a doctor's recommendation to stay on the drugs, Mahoney said. That reality, not the lifelong-use pitch that dominates the category, drives Noom's argument for pairing any prescription with coach-led habit tools.

The smart-home spot will run alongside those testimonials as the "Lose for Keeps" platform enters its GLP-1-aware phase, putting Noom in a small group of weight-loss brands advertising directly against the rebound risk their customers face.